Serial 88514434
Live / Registered — Registered (as of 04 May 2021)
What this means for you
Registered since 04 May 2021. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88514434
- Registration number
- 6342347
- Mark type
- Design / logo
- Filed
- 15 Jul 2019
- Published for opposition
- 25 Feb 2020
- Registered
- 04 May 2021
- Attorney of record
- Paul C. Llewellyn
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
Owner
- Sarepta Therapeutics, Inc., Cambridge, MA, US
- Sarepta Therapeutics, Inc., Cambridge, MA, US
- Sarepta Therapeutics, Inc., Cambridge, MA, US
Prior registrations
Prosecution history
- 04 May 2021 — REGISTERED-PRINCIPAL REGISTER
- 02 Apr 2021 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 01 Apr 2021 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 19 Mar 2021 — STATEMENT OF USE PROCESSING COMPLETE
- 01 Mar 2021 — USE AMENDMENT FILED
- 19 Mar 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 01 Mar 2021 — TEAS STATEMENT OF USE RECEIVED
- 17 Oct 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Oct 2020 — SOU EXTENSION 1 GRANTED
- 15 Oct 2020 — SOU EXTENSION 1 FILED
- 15 Oct 2020 — SOU TEAS EXTENSION RECEIVED
- 21 Apr 2020 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 25 Feb 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 Feb 2020 — PUBLISHED FOR OPPOSITION
- 05 Feb 2020 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED